Skip to content Skip to main menu
SCROLL

Our Science

Everybody possesses a unique microbiome composed of trillions of bacteria that release nano-sized extracellular vesicles (EVs) throughout our body. After over a decade of research on the relationship between the microbial EVs in our bodies and chronic illness, we created a one-of-a-kind precision medicine platform to provide innovativesolutions to modern healthcare needs.

SCROLL

Pipelines

By harnessing the dynamic activity of the human microbiome,
we are developing drug and IVD pipelines with a strong foundational IPR.

Drug Pipeline

We are exploring the therapeutic applications of human microbiota-derived extracellular vesicles (EVs) in cancer immunotherapy as well as range of indications including central nervous system (CNS), metabolic, allergic and respiratory diseases.

View More

IVD Pipeline

By analyzing the microbiome activity of thousands of clinical samples via extracellular vesicles (EVs), we are developing in vitro diagnostic (IVD) pipelines to assess disease risk for a breadth of cancers and chronic illnesses to provide healthcare providers with modern tools for 21st century medicine.

View More

Strong IPR

MD Healthcare’s core strength lies in our strong intellectual property right (IPR) as pioneers in the field of microbiome extracellular vesicle (EVs) research.
With over 50 international and domestic patents registered for the use of various microbial EVs for therapeutic and diagnostic applications.

View More
SCROLL
SCROLL

News & Media

Stay up to date on MD Healthcare’s business & research developments as well as our activity in the media.

  • Business

    Collaborative development of “Mogurt” symbiotic beverage

    In collaboration with Dankook Univ. Hospital’s Prof. Young Goo gi and Coenbio, we developed a synbiotic beverage containing perbiotics and probiotics derived from kimchi. Consumption of this beverage was shown to alter microbiome activity and reduve blood AST levels.

    For more information, read our article published in Nature EMM.

    December 04, 2019

  • Research

    Reduction of Colorectal Cancer Risk Through Grain Diet

    We found significant differences in stool bacterial composition between CRC and healthy subject and developed a diagnositc model to assess CRC risk. Further, we showed that comsumption of certatin grains reduced CRC risk associated with high fat diet in a mouse model.

    For more information, read our article published in Nature EMM.

    December 04, 2019

  • Media

    Why is Personalized Precision Medicine Necessary?

    Our CEO Yeun Keun Kim disussed the importance the relationship between the microbiome and autism at Korea’s first Autism Expo in 2019. At our booth, attendees learned about our advances in microbiome-based diagnosis and foods designed to reduce individual disease risk.

    To read the whole story, check out the article at Human Aid Post

    December 04, 2019

View More

Contact Us